TOVX 8-K: Stock split
Filed with the SEC on · accession 0001104659-26-130644
TOVX filed a 8-K (current report) with the SEC on Nov 20, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Summary of the filing
Theriva Biologics' Board of Directors approved a 1-for-30 reverse stock split of the company's common stock, expected to be effective December 1, 2026, with split-adjusted trading beginning December 2, 2026.
Key details
✦ Ask GOAX AI about this filing — what it means for TOVX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for TOVX?
Click hereFrequently asked questions
What did TOVX file with the SEC on Nov 20, 2026?
TOVX filed a 8-K (Stock split). Theriva Biologics' Board of Directors approved a 1-for-30 reverse stock split of the company's common stock, expected to be effective December 1, 2026, with split-adjusted trading beginning December 2, 2026.
What does a stock split mean for TOVX stock?
Usually: fewer shares means each remaining share owns more of the company. It matters whether the company actually buys and at what price.
How do I read a 8-K?
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Other TOVX SEC filings
Get alerts when TOVX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days